Journal Publications

Export 12 results:
Author Title Type [ Year(Asc)]
Filters: First Letter Of Title is I  [Clear All Filters]
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. Jose S, Nelson M, Phillips A, Chadwick D, Trevelion R, Jones R, Williams D, Hamzah L, Sabin C and Post F. AIDS, 2017 Feb 20, Volume 31, Issue 4, p.485-492, (2017)
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro M, Günthard H, Wittkop L, Kordossis T, García F et al. J Antimicrob Chemother, 2016 May, Volume 71, Issue 5, p.1352-60, (2016)
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. May M, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R et al. AIDS, 2014 May 15, Volume 28, Issue 8, p.1193-202, (2014)
The increasing genetic diversity of HIV-1 in the UK, 2002-2010. . AIDS, 2014 Mar 13, Volume 28, Issue 5, p.773-80, (2014)
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. Jose S, Hamzah L, Campbell L, Hill T, Fisher M, Leen C, Gilson R, Walsh J, Nelson M, Hay P et al. J Infect Dis, 2014 Aug 01, Volume 210, Issue 3, p.363-73, (2014)
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. Mackie N, Dunn D, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C and Geretti A. AIDS, 2013 Sep 10, Volume 27, Issue 14, p.2245-53, (2013)
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Mocroft A, Furrer H, Miro J, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D et al. Clin Infect Dis, 2013 Oct, Volume 57, Issue 7, p.1038-47, (2013)
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B et al. BMJ, 2011 Oct 11, Volume 343, p.d6016, (2011)
The impact of HIV drug resistance testing on changes to treatment. Bansi L, Smith C, Phillips A, Kirk S, Geretti A, Johnson M, Mackie N, Post F, Gazzard B, Dunn D et al. AIDS, 2011 Mar 13, Volume 25, Issue 5, p.603-10, (2011)
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). Bansi L, Geretti A, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A et al. J Acquir Immune Defic Syndr, 2010 Apr, Volume 53, Issue 5, p.633-9, (2010)
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo A, Mocroft A, Bonnet F, Clifford G, Karafoulidou A et al. Antivir Ther, 2009, Volume 14, Issue 8, p.1065-74, (2009)
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. Benzie A, Bansi L, Sabin C, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P, Gazzard B, Fisher M et al. AIDS, 2007 Jul 11, Volume 21, Issue 11, p.1423-30, (2007)